Palonosetron+Aprepitant+Dexamethasone for moderately emetic chemotherapy induced nausea and voimiting-Phase II study
Phase 2
- Conditions
- ung cancer
- Registration Number
- JPRN-UMIN000004936
- Lead Sponsor
- iigata Lung Cancer Treatment Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 160
Inclusion Criteria
Not provided
Exclusion Criteria
1)MEC administration except Day 1. 2)Radiation therapy 3)Contraindication of Dexamethasone 4)Symptomatic brain meta 5)Hypersensitivity for Palonosetron, Aprepitant, Dexamethasone 6)Vomiting episode prior to chemotherapy with 24 hours
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Complete response rate in 1st course of chemotherapy
- Secondary Outcome Measures
Name Time Method Complete response rate in any course of chemotherapy Complete control rate Time to treatment failure QOL analysis Toxicity